NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
March 20 2024 - 7:00AM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology
testing services company, today released its 2023 Environmental,
Social, and Governance (ESG) Report highlighting progress toward
building a more sustainable, diverse, and equitable company that
delivers exceptional customer experience and advanced testing
options. This inaugural report details the performance and
management of NeoGenomics’ commitment to its core values of
quality, integrity, accountability, teamwork, and innovation.
“Releasing our first ESG report marks an important milestone in
NeoGenomics’ growth and evolution,” said Chris Smith, CEO at
NeoGenomics. “Through these efforts, we have established
foundational pillars to serve as a beacon for building a
sustainable company that provides exceptional customer experience
and advanced testing options.”
The 2023 ESG Report measures progress on key sustainability
focus areas, including Customer Privacy, Data and Cybersecurity,
Recruitment, Development and Retention, Business Ethics, Product
Quality and Safety, Legal and Regulatory Environment, and
Environmental Stewardship.
Highlights of the report include:
- Progressing diversity, equity, inclusion, and belonging
efforts. NeoGenomics continues its commitment to maintaining a
supportive workplace, which includes investing in ongoing
opportunities for teammate development in a diverse and inclusive
environment. At the end of 2023, women comprised 59.9% of the
global workforce, 53.5% of the US workforce was ethnically diverse,
and 73% of employees had been impacted by cancer.
- Pursuing environmental stewardship. In 2023, NeoGenomics
recycled 310 tons of waste from its labs in Fort Myers, FL, and
Aliso Viejo, CA. The NeoGreen program allowed for 24.5% of all
waste to be recycled.
- Protecting stakeholders with strong corporate
governance. NeoGenomics expanded its Board of Directors by
appointing three new independent board members with over 50 years
of executive experience in digital technologies, global marketing,
and molecular diagnostics.
- Promoting teammate growth and engagement. NeoGenomics’
2023 Employee Engagement Survey showed net improvements in Employee
Happiness and Employee Engagement and decreased voluntary employee
turnover to 13%.
“While completing our research and aggregating the data for the
report, it quickly became apparent that ESG principles have been at
the core of our work for some time now,” added Smith. “I am more
optimistic than ever about what lies ahead for NeoGenomics. Our
2024 plans and pipeline will move us closer to serving 1 million
patients annually by 2028.”
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company's Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates
CAP-accredited and CLIA-certified laboratories for full-service
sample processing in Fort Myers, Florida; Aliso Viejo and San
Diego, California; Research Triangle Park, North Carolina; and
Houston, Texas; and a CAP-accredited full-service,
sample-processing laboratory in Cambridge, United Kingdom.
NeoGenomics also has several small, non-processing laboratory
locations across the United States for providing analysis services.
NeoGenomics serves the needs of pathologists, oncologists, academic
centers, hospital systems, pharmaceutical firms, integrated service
delivery networks, managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320977067/en/
Investor Contact Kendra Sweeney Vice President, Investor
Relations and ESG kendra.sweeney@neogenomics.com
Media Contact Andrea Sampson President/CEO, Sampson
Public Relations Group asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoGenomics (NASDAQ:NEO)
Historical Stock Chart
From Jul 2023 to Jul 2024